|
|
|
|
|||||
|
|
|
Sanofi (NASDAQ:SNY) is one of the Cheap NASDAQ Stocks to Buy Now. On December 4, Sanofi (NASDAQ:SNY) announced the completion of the Vicebio acquisition. Vicebio is a clinical-stage biotechnology company focused on developing transformative multi-pathogen vaccines for respiratory viral infections.
Management noted that this strategic acquisition brings Vicebio’s early-stage vaccine candidate for respiratory syncytial virus and human metapneumovirus under Sanofi’s portfolio. Moreover, the company also noted that the acquisition will allow it to enhance vaccine design and development using Vicebio’s Molecular Clamp technology.
Earlier on November 25, Sanofi (NASDAQ:SNY) announced that its jointly developed program with Regeneron called Dupilumab was approved by the European Commission to treat moderate-to-severe chronic spontaneous urticaria in adult and adolescent patients 12 years and above. Management noted that Dupilumab can be used as a first-line targeted treatment option.
The EU approval was based on positive results from the Phase 3 study, which showed Dupilumab reduced symptoms at 24 weeks compared to the placebo. The addressable market in the EU is significant, as there are over 270,000 adults and adolescents aged 12 years and older with chronic spontaneous urticaria.
Sanofi (NASDAQ:SNY) researches, produces, and distributes pharmaceutical products. The company’s operations are divided into the Pharmaceuticals, Consumer Healthcare, and Vaccines segments.
While we acknowledge the potential of SNY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
| Dec-09 | |
| Dec-09 | |
| Dec-09 | |
| Dec-08 | |
| Dec-05 | |
| Dec-05 | |
| Dec-04 | |
| Dec-01 | |
| Nov-28 | |
| Nov-26 | |
| Nov-26 | |
| Nov-26 | |
| Nov-26 | |
| Nov-25 | |
| Nov-20 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite